The stock of Lexeo Therapeutics Inc (LXEO) has seen a -5.99% decrease in the past week, with a 28.88% gain in the past month, and a 39.47% flourish in the past quarter. The volatility ratio for the week is 4.92%, and the volatility levels for the past 30 days are at 7.64% for LXEO. The simple moving average for the past 20 days is 22.21% for LXEO’s stock, with a -26.69% simple moving average for the past 200 days.
Is It Worth Investing in Lexeo Therapeutics Inc (NASDAQ: LXEO) Right Now?
The stock has a 36-month beta value of 0.45. Opinions on the stock are mixed, with 4 analysts rating it as a “buy,” 3 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for LXEO is 25.03M, and at present, short sellers hold a 15.10% of that float. On June 19, 2025, the average trading volume of LXEO was 1.02M shares.
LXEO) stock’s latest price update
The stock of Lexeo Therapeutics Inc (NASDAQ: LXEO) has increased by 8.16 when compared to last closing price of 3.92.Despite this, the company has seen a loss of -5.99% in its stock price over the last five trading days. globenewswire.com reported 2025-05-27 that Lexeo Therapeutics Announces $80 Million Equity Financing to Further Advance Development of Transformative Genetic Medicines for Cardiovascular Diseases
Analysts’ Opinion of LXEO
Many brokerage firms have already submitted their reports for LXEO stocks, with Robert W. Baird repeating the rating for LXEO by listing it as a “Outperform.” The predicted price for LXEO in the upcoming period, according to Robert W. Baird is $28 based on the research report published on June 13, 2024 of the previous year 2024.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see LXEO reach a price target of $22. The rating they have provided for LXEO stocks is “Buy” according to the report published on June 06th, 2024.
Stifel gave a rating of “Buy” to LXEO, setting the target price at $20 in the report published on November 28th of the previous year.
LXEO Trading at 30.51% from the 50-Day Moving Average
After a stumble in the market that brought LXEO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -78.26% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at LXEO starting from Townsend Richard Nolan, who sale 1,074 shares at the price of $2.77 back on May 16 ’25. After this action, Townsend Richard Nolan now owns 221,173 shares of Lexeo Therapeutics Inc, valued at $2,979 using the latest closing price.
Adler Eric, the Chief Medical Officer of Lexeo Therapeutics Inc, sale 585 shares at $2.77 during a trade that took place back on May 16 ’25, which means that Adler Eric is holding 67,681 shares at $1,623 based on the most recent closing price.
Stock Fundamentals for LXEO
The total capital return value is set at -1.23. Equity return is now at value -80.65, with -64.51 for asset returns.
Based on Lexeo Therapeutics Inc (LXEO), the company’s capital structure generated 0.1 points at debt to capital in total, while cash flow to debt ratio is standing at -9.36. The debt to equity ratio resting at 0.11. The interest coverage ratio of the stock is -908.44.
Currently, EBITDA for the company is -96.22 million with net debt to EBITDA at 0.18. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.42.
Conclusion
To sum up, Lexeo Therapeutics Inc (LXEO) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
